|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.26 - 11:39
|
Novo Nordisk: Der nächste Angriff ist bereits im Gange (Der Aktionaer)
|
|
|
Eli Lilly hat einen kräftigen Sprung nach vorn gemacht und liegt im Ranking der Diabetes-Pharmahersteller nun dicht hinter Novo. Grundlage ist eine Befragung von PatientView unter 71 Patientengruppen in 30 Ländern. Bei den Unternehmen, mit denen die Gruppen zusammenarbeiten, folgen auf Novo Lilly und Sanofi....
|
|
|
|
|
|
|
|
|
22.10.26 - 04:16
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight (ZeroHedge)
|
|
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
Authored by Paul D. Thacker via The DisInformation Chronicle,
New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR firm Weber Shandwick which represents most major vaccine manufacturers.
I'm not joking. This is the journalism I get for my paid subscription to the New York Times.
Like most senior executives at the global PR firm Weber Shandwick, Jack Leslie makes buckets of money helping corporations sell themselves and their products to the American public. In the last handful of years, Weber Shandwick's clients have included the bulk of the global vaccine giants including Pfizer, Moderna, GSK, Sanofi, Novartis, and Eli Lilly.
But when he's not raking in oodles of cash repping corporate America, Leslie also takes on some unpaid healthcare...
|
|
|
21.10.26 - 15:42
|
Sanofi Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi vor den am 30. Oktober erwarteten Quartalszahlen auf "Neutral" mit einem Kursziel von 85 Euro belassen. Analyst Richard Vosser verglich in einer am Mittwoch vorliegenden ......
|
|
|
21.10.26 - 12:12
|
Sanofi and ScionxBio partner on mRNA therapies (PBR)
|
|
|
Under the arrangement, the companies will create extended-exposure formulations of selected mRNA candidates from Sanofi by applying ScionxBio's TERA technology. The partnership divides research and clinical duties between
The post Sanofi and ScionxBio partner on mRNA therapies appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
